BlackRock’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $161M | Sell |
|
|||||
|
2025
Q2 | $192M | Sell |
|
|||||
|
2025
Q1 | $171M | Buy |
|
|||||
|
2024
Q4 | $166M | Buy |
|
|||||
|
2024
Q3 | $159M | Buy |
|
|||||
|
2024
Q2 | $123M | Buy |
|
|||||
|
2024
Q1 | $93.7M | Sell |
|
|||||
|
2023
Q4 | $112M | Buy |
|
|||||
|
2023
Q3 | $119M | Buy |
|
|||||
|
2023
Q2 | $109M | Buy |
|
|||||
|
2023
Q1 | $124M | Sell |
|
|||||
|
2022
Q4 | $171M | Buy |
|
|||||
|
2022
Q3 | $174M | Sell |
|
|||||
|
2022
Q2 | $148M | Sell |
|
|||||
|
2022
Q1 | $229M | Sell |
|
|||||
|
2021
Q4 | $205M | Sell |
|
|||||
|
2021
Q3 | $220M | Sell |
|
|||||
|
2021
Q2 | $245M | Sell |
|
|||||
|
2021
Q1 | $165M | Sell |
|
|||||
|
2020
Q4 | $121M | Buy |
|
|||||
|
2020
Q3 | $54.8M | Buy |
|
|||||
|
2020
Q2 | $69.9M | Buy |
|
|||||
|
2020
Q1 | $26.8M | Buy |
|
|||||
|
2019
Q4 | $41.9M | Buy |
|
|||||
|
2019
Q3 | $27.5M | Buy |
|
|||||
|
2019
Q2 | $33.8M | Buy |
|
|||||
|
2019
Q1 | $70.8M | Sell |
|
|||||
|
2018
Q4 | $71.4M | Buy |
|
|||||
|
2018
Q3 | $66.9M | Buy |
|
|||||
|
2018
Q2 | $44.4M | Buy |
|
|||||
|
2018
Q1 | $35.7M | Sell |
|
|||||
|
2017
Q4 | $37.4M | Buy |
|
|||||
|
2017
Q3 | $34.7M | Buy |
|
|||||
|
2017
Q2 | $34.8M | Buy |
|
|||||
|
2017
Q1 | $50.5M | Buy |
|
|||||
|
2016
Q4 | $65K | Buy |
|
|||||
|
2016
Q3 | $44K | Sell |
|
|||||
|
2016
Q2 | $48K | Buy |
|
|||||
|
2016
Q1 | $14K | Buy |
|
|||||
|
2015
Q4 | $21K | Buy |
|
|||||
|
2015
Q3 | $17K | Sell |
|
|||||
|
2015
Q2 | $900K | Sell |
|
|||||
|
2015
Q1 | $575K | Hold |
|
|||||
|
2014
Q4 | $774K | Hold |
|
|||||
|
2014
Q3 | $622K | Sell |
|
|||||
|
2014
Q2 | $866K | Buy |
|
|||||
|
2014
Q1 | $0 | Buy |
|